Cardiovascular Surgical Devices Market, Size, Share, Global Forecast 2024-2032, Industry Trends, Growth, Insight, Top Companies Analysis

Cardiovascular Surgical Devices Market, Size, Share, Global Forecast 2024-2032, Industry Trends, Growth, Insight, Top Companies Analysis

Cardiovascular Surgical Devices Market is predicted to reach US$ 2.77 Billion by 2032, according to Renub Research. Lately, cardiovascular surgical gadgets have received prominence inside the healthcare sector thanks to their large impact on affected person remedy. These devices give modern solutions for addressing numerous cardiovascular illnesses, spanning from minimally invasive processes to elaborate surgical procedures. Their precision, effectiveness, and ability to shorten affected person restoration durations have captured the interest of healthcare specialists globally. Moreover, technological progressions have improved the protection and performance of these devices, rendering them increasingly attractive to both practitioners and sufferers looking for top-rated consequences in contemporary cardiovascular healthcare.

Cardiovascular Surgical Devices Market is anticipated to increase at a CAGR of 3.46% from 2024 to 2032

The surge in cardiac illnesses, diabetes, and lifestyle disorders contributes considerably to the growth of the cardiac surgical devices market. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the primary global reason of mortality, claiming approximately 17.9 million lives yearly. Over four-fifths of CVD-related deaths stem from heart attacks and strokes, with a third occurring prematurely in individuals under 70. Key behavioral risk elements for heart sickness and stroke encompass harmful nutritional patterns, a loss of physical activity, tobacco consumption, and excessive alcohol consumption.

Over the past decade, improvements in cardiac device technologies and their warning signs have propelled the cardiovascular surgical devices market. Improved technology yields higher patient outcomes, shorter recovery instances, and higher satisfaction rates. Artificial intelligence is one such technology that substantially enhances cardiology by imparting advanced monitoring abilities. For example, in 2023, Eko launched the SENSORA™ Cardiac Disease Detection Platform, which uses AI to detect structural murmurs, aiding in valvular heart disorder diagnosis. Expanded tool indicators widen their scope in addressing diverse cardiovascular issues, fostering market growth and adoption. Hence, the Cardiovascular Surgical Devices Market was worth US$ 2.04 Billion in 2023.

The reaction to heightened demands for cardiovascular surgical devices in developing nations also contributed to the market boom. For instance, in 2022, Abbott launched its contemporary-technology transcatheter aortic valve implantation (TAVI) device, Navitor, which increased access to minimally invasive remedies for intense aortic stenosis patients in India at excessive or intense surgical danger. Aortic stenosis, a general and severe coronary heart valve disorder, frequently lacks considerable signs. However, 4.54 per thousand individuals in India suffer from this condition, according to the National Institutes of Health (NIH).

Moreover, the surge in approvals from the regulatory authorities for groundbreaking products extensively drives the market's growth. Also, product launches, approvals, strategic acquisitions, and improvements are vital enterprise techniques employed by cardiovascular surgical devices market participants to maintain and expand their worldwide presence. For example, in 2023, Abbott and Cardiovascular Systems, Inc. disclosed a definitive agreement for Abbott to gather CSI, a medical device corporation famous for its revolutionary atherectomy machine used in addressing peripheral and artery disease. This acquisition will augment Abbott's leading vascular device portfolio with complementary technologies from CSI.

Cardiac arrhythmia plays a crucial role in the market for cardiovascular surgical devices

Based on Application, the Cardiovascular Surgical Devices Market is categorized into Congenital Heart Defects, Cardiac Arrhythmia, Coronary Heart Disease, Congestive Heart Failure, and Others. Cardiac arrhythmia is pivotal in the cardiovascular surgical devices market because of its prevalence and life-threatening implications. This spurs demand for modern solutions like pacemakers and catheter ablation structures. For instance, in 2024, Boston Scientific Corporation received FDA approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System, offering a unique technique for treating drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.

China significantly influences the market for cardiovascular surgical devices

The Cardiovascular Surgical Devices Market is split by country, including North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, the Netherlands, and Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and New Zealand), Latin America (Brazil, Mexico, and Argentina), Middle East & Africa (South Africa, Saudi Arabia, and the United Arab Emirates). China is important in the cardiovascular surgical devices market. This is due to its vast population, rising cardiovascular disorder rates, expanding healthcare infrastructure, increasing healthcare expenditure, and developing need for superior scientific technologies. For instance, in July 2022, China's National Medical Products Administration permitted an artificial coronary heart for excessive heart failure created by the China Academy of Launch Vehicle Technology and TEDA International Cardiovascular Hospital.

Key Players

The Cardiovascular Surgical Devices Market includes companies such as Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences, Cardinal Health Inc., Medtronic PLC, GE Healthcare, LivaNova PLC, and Terumo Corporation.

Product Type – Market breakup in 4 viewpoints:

1. Beating Heart Surgery Systems
2. Cardiopulmonary Bypass Equipment
3. Cardiac Ablation Devices
4. Perfusion Disposable

Application – Market breakup in 5 viewpoints:

1. Congenital Heart Defects
2. Cardiac Arrhythmia
3. Coronary Heart Disease
4. Congestive Heart Failure
5. Others

End-User – Market breakup in 3 viewpoints:

1. Hospitals
2. Ambulatory Surgical Centers
3. Others

Country – Market of 25 Countries Covered in the Report:

1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. Abbott Laboratories
2. Boston Scientific Corporation
3. Edwards Lifesciences
4. Cardinal Health Inc.
5. Medtronic PLC
6. GE Healthcare
7. LivaNova PLC
8. Terumo Corporation